Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 2433334 dose-finding study after acute myocardial infarction
NL-OMON54974Phase 2Active, not recruiting
- Sponsor
- Bayer
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of asundexian in myocardial infarction (MI) and acute coronary syndrome (ACS) (4 arms), sponsored by Bayer. Primary endpoints: Composite of cardiovascular death, myocardial infarction, stroke, and stent thrombosis and BARC bleeding type 2, 3, and 5. Started Aug 2020; status: active, not recruiting.
02
Drugs
asundexian
03
Conditions
myocardial infarction (MI)acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NL-OMON54974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54974.